- Joined
- Dec 3, 2017
- Messages
- 23,519
- Reaction score
- 14,043
- Gender
- Male
- Political Leaning
- Progressive
Metocurine - Wikipedia
Original Research
Published: 11 August 2020
Repurposing metocurine as main protease inhibitor (Mpro) to develop novel antiviral therapy for COVID-19
Repurposing metocurine as main protease inhibitor to develop novel antiviral therapy for COVID-19 | SpringerLink
The drug development process is a very complex process which desires so many years as well as large approach of money for discovery of new chemical entities (NCEs). To overcome the high cost and time required for developing a drug molecule, in silico drug repurposing and repositioning techniques are promising alternative methods. In the current paradigm of conventional drug discovery process, the drug repurposing approach reveals an alternative economical and time-saving substitute having a higher success rate. Drug repurposing is a technique in which a newer pharmacological application of an existing drug is identified and established through computational and clinical investigations. Drug repurposing and repositioning techniques are extensively applied in the modern era for the successful development of newer therapy for the diseased condition via existing drugs. In the earlier days, the newer pharmacological role of an existing drug was identified by its accidental use or either observed by their clinical manifestations. Nowadays, fast, economical, reliable, and versatile computational repurposing techniques were utilized to recognize a newer functional role of an existing drug molecule.
===============================================================
Metocurine is a competitive non-depolarizing neuromuscular blocking agent used as a muscle relaxant as well as an anesthetic agent. The metocurine interacts within the active binding cavity of viral Mpro enzyme by mainly with the Phe140, Leu141, Cys145, His163, His164, Met165, Glu166, Leu167, and Pro168 residues.
==============================================================================
It was observed that metocurine was found to be a potential lead molecules against the viral Mpro enzyme of COVID-19. Based on their safety profile, metocurine was chosen as a safe and effective drug candidate for developing therapy against the viral Mpro enzyme of SARS-CoV-2 for the treatment of COVID-19.
======================================================
Comments: with powerful computational analytical techniques, existing drug molecules can be rapidly screened for potential activity against covid-19. In this study the existing approived drug metocurine was found to be a likely candidate to inhibit the Main protease enzyme Mpro. If Mpro is inhibited, the virus dies.
See related molecule ebselen posted previously.
Original Research
Published: 11 August 2020
Repurposing metocurine as main protease inhibitor (Mpro) to develop novel antiviral therapy for COVID-19
Repurposing metocurine as main protease inhibitor to develop novel antiviral therapy for COVID-19 | SpringerLink
The drug development process is a very complex process which desires so many years as well as large approach of money for discovery of new chemical entities (NCEs). To overcome the high cost and time required for developing a drug molecule, in silico drug repurposing and repositioning techniques are promising alternative methods. In the current paradigm of conventional drug discovery process, the drug repurposing approach reveals an alternative economical and time-saving substitute having a higher success rate. Drug repurposing is a technique in which a newer pharmacological application of an existing drug is identified and established through computational and clinical investigations. Drug repurposing and repositioning techniques are extensively applied in the modern era for the successful development of newer therapy for the diseased condition via existing drugs. In the earlier days, the newer pharmacological role of an existing drug was identified by its accidental use or either observed by their clinical manifestations. Nowadays, fast, economical, reliable, and versatile computational repurposing techniques were utilized to recognize a newer functional role of an existing drug molecule.
===============================================================
Metocurine is a competitive non-depolarizing neuromuscular blocking agent used as a muscle relaxant as well as an anesthetic agent. The metocurine interacts within the active binding cavity of viral Mpro enzyme by mainly with the Phe140, Leu141, Cys145, His163, His164, Met165, Glu166, Leu167, and Pro168 residues.
==============================================================================
It was observed that metocurine was found to be a potential lead molecules against the viral Mpro enzyme of COVID-19. Based on their safety profile, metocurine was chosen as a safe and effective drug candidate for developing therapy against the viral Mpro enzyme of SARS-CoV-2 for the treatment of COVID-19.
======================================================
Comments: with powerful computational analytical techniques, existing drug molecules can be rapidly screened for potential activity against covid-19. In this study the existing approived drug metocurine was found to be a likely candidate to inhibit the Main protease enzyme Mpro. If Mpro is inhibited, the virus dies.
See related molecule ebselen posted previously.
Last edited: